Narrowly Defined Drug Patient Assistance Programs Spark OIG Advisory
This article was originally published in The Pink Sheet Daily
Executive Summary
The HHS Office of Inspector General will give greater scrutiny to patient assistance programs that help enrollees in Medicare Part D plans purchase drugs if they only help patients with narrowly defined diseases or limit the range of drugs they will help cover, OIG says in updated guidance.
You may also be interested in...
Reimbursement Support Programs Create 'Holy Trinity' Of Enforcement Risk
Services that help doctors' offices navigate payment hurdles could draw government scrutiny for false claims, kickbacks, and medical privacy violations, attorney says.
GSK's Nucala Is Significantly Overpriced, ICER Draft Report Finds
New biologic for severe asthma doesn't stack up well to standard of care on generally accepted levels of cost per quality-adjusted life year.
Deal Watch: Sanofi, Boehringer Swap Side Businesses
Busy week for AstraZeneca sees buyout of Acerta and acquisition of remaining Daliresp/Daxas worldwide rights from Takeda. Amgen and GSK undo their cancer drug alliances from 2009 and 2010, with all rights reverting to the big biotech.